消瘀康胶囊联合尤瑞克林治疗急性脑梗死的效果分析

摘要/Abstract

摘要： 目的研究消瘀康胶囊联合尤瑞克林治疗急性脑梗死的疗效。方法选择2019年1月—2023年1月大理白族自治州人民医院收治的92例急性脑梗死患者作为研究对象,按照干预方式的不同将其分为对照组和观察组,各46例。对照组采用尤瑞克林治疗,观察组在对照组治疗的基础上联用消瘀康胶囊治疗。计算两组治疗有效率,检测两组的临界压力（CP）、脉搏波数（Wv）、最小血流量（Qmin）、动态阻抗（DR）、脑血管外周阻力（R）和颈动脉最小血流速度（Vmin）,且检测血清生长分化因子15（GDF-15）、CXC趋化因子16（CXCL-16）、正五聚蛋白3（PTX3）和单核细胞趋化蛋白1（MCP-1）水平。结果观察组的治疗有效率明显高于对照组,差异有统计学意义（P<0.05）;治疗前,两组的CP、Wv、Qmin、DR、R和Vmin比较,差异无统计学意义（P>0.05）,治疗后,两组的CP、Wv、Qmin、DR、R和Vmin均明显改善,且观察组的CP、Wv、Qmin、DR、R和Vmin改善明显优于对照组,差异有统计学意义（P<0.05）;治疗前,两组的血清GDF-15、CXCL-16、PTX3和MCP-1水平比较,差异无统计学意义（P>0.05）,治疗后,两组的血清GDF-15、CXCL-16、PTX3和MCP-1水平均明显降低,且观察组的血清GDF-15、CXCL-16、PTX3和MCP-1水平明显低于对照组,差异有统计学意义（P<0.05）。治疗前,两组Barthal指数比较,差异无统计学意义（P>0.05）,治疗后,两组Barthal指数评分均明显升高,且观察组高于对照组,差异有统计学意义（P<0.05）。观察组的不良反应发生率明显低于对照组,差异有统计学意义（P<0.05）。结论采用消瘀康胶囊联合尤瑞克林治疗能明显提高急性脑梗死的疗效,改善脑血流动力学,减轻炎症反应,提高患者日常生活能力,且安全性高。

关键词: 消瘀康胶囊, 尤瑞克林, 急性脑梗死, 血流动力学, 炎症因子

Abstract: Objective To investigate the effect of Xiaoyukang capsule combined with Urinary Kallidinogenase in the treatment of acute cerebral infarction. Methods A retrospective analysis was conducted on the clinical data of 92 patients with acute cerebral infarction admitted to the People's Hospital of Dali Bai Autonomous Prefecture from January 2019 to January 2023. They were divided into two groups according to different intervention methods. The control group used Urinary Kallidinogenase, while the observation group was treated with Xiaoyukang capsules in combination with the control group.The effective rates of two treatment groups were calculated, critical pressure (CP), pulse wave number (Wv), minimum blood flow (Qmin), dynamic impedance (DR), peripheral resistance of cerebral vessels (R) and minimum blood flow velocity of carotid arteries (Vmin) were measured in the two groups, and serum levels of growth differentiation factor 15 (GDF-15), CXC chemokine 16 (CXCL-16), pentameric protein 3 (PTX3) and Monocyte chemotactic protein 1 (MCP-1) were measured. Results The effective rate of the observation group was significantly higher than control group (P<0.05). Before treatment, there was no significant difference in CP, Wv, Qmin, DR, R, and Vmin between the two groups (P>0.05). After treatment, the CP, Wv, Qmin, DR, R, and Vmin of the two groups were significantly improved (P<0.05), and the CP, Wv, Qmin, DR, R, and Vmin of the observation group were significantly better than those of the control group (P<0.05). Before treatment, there was no significant difference in serum levels of GDF-15, CXCL-16, PTX3, and MCP-1 between the two groups (P>0.05). After treatment, the serum levels of GDF-15, CXCL-16, PTX3, and MCP-1 in both groups were significantly reduced (P<0.05), and the serum levels of GDF-15, CXCL-16, PTX3, and MCP-1 in the observation group were significantly lower than those in the control group (P<0.05). Before treatment, there was no statistically significant difference in Barthal index between the two groups (P>0.05). After treatment, the Barthal index scores of the two groups significantly increased (P<0.05), and the observation group was higher than the control group (P<0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P<0.05). Conclusion The combination of Xiaoyukang Capsules and Urinary Kallidinogenase can significantly improve the therapeutic effect of acute cerebral infarction, improve cerebral hemodynamics, reduce inflammatory reactions, improve patients'daily living ability, and have high safety.

Key words: Xiaoyukang Capsules, yuriklin, acute cerebral infarction, hemodynamics, inflammatory factors

中图分类号:

R743.3

王俊, 熊佳, 李旭芳. 消瘀康胶囊联合尤瑞克林治疗急性脑梗死的效果分析[J]. 中华养生保健, 2024, 42(16): 31-34.

WANG Jun, XIONG Jia, LI Xu-fang. Analysis of the Effect of Xiaoyukang Capsule Combined with Urinary Kallidinogenase in the Treatment of Acute Cerebral Infarction[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(16): 31-34.

参考文献

[1] 马利菊,杜平,孙许锋,等.复方丹参滴丸联合阿托伐他汀对急性脑梗死患者颈动脉粥样硬化斑块稳定性超声参数及血清LDL-C和D-D的影响[J].现代中西医结合杂志,2022,31(15):2141-2145.
[2] 王雪利,谢静红,蒋利魁.地黄饮子加减对急性脑梗死患者血清NO,Caspase-3,Bcl-2,Bax水平的影响[J].中医药信息,2022,39(8):60-70.
[3] 崔传举,王玉香,燕燕,等.脑苷肌肽联合尤瑞克林治疗急性脑梗死疗效观察[J].新乡医学院学报,2022,39(7):659-663.
[4] 许西海,高艳,王玉华,等.消瘀康胶囊联合三磷酸胞苷二钠治疗脑出血恢复期的临床研究[J].现代药物与临床,2022,37(4):765-769
[5] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,51(9):666-682.
[6] 刘惠钦,范月辉,孟丽,等.消栓通络胶囊联合尤瑞克林治疗急性脑梗死的临床研究[J].现代药物与临床,2022,37(12):2760-2764.
[7] 乔天慈,吴宏赟,李浩然,等.炙黄芪-水蛭治疗阿替普酶静脉溶栓的气虚血瘀型急性脑梗死的临床疗效观察[J].中医药学报,2022,50(4):63-67.
[8] 孟甜甜,田紫煜,解小龙,等.银杏叶片治疗急性脑梗死临床疗效和安全性的系统评价与Meta分析[J].中国中药杂志,2021,46(6):1537-1546.
[9] 许西海,高艳,王玉华,等.消瘀康胶囊联合三磷酸胞苷二钠治疗脑出血恢复期的临床研究[J].现代药物与临床,2022,37(4):765-769.
[10] 赵凯,张强,杨明飞,等.消瘀康胶囊在慢性硬膜下血肿吸收中的研究[J].中国全科医学,2021,24(S01):166-168.
[11] 吴松,金肇权,孙丹,等.注射用鼠神经生长因子联合注射用重组人TNK组织型纤溶酶原激活剂治疗急性脑梗死患者的临床研究[J].中国临床药理学杂志,2022,38(3):199-202.
[12] 李露露,宋圆英,胡馨予,等.丹参-川芎药对治疗脑梗死作用机制的网络药理及分子对接研究[J].成都中医药大学学报,2022,45(1):44-51.
[13] 袁蓉,施伟丽,信琪琪,等.川芎—赤芍药对研究进展[J].环球中医药,2019,12(5):808-811.
[14] 张永兵,程延娜.消瘀康胶囊联合颅内血肿微创清除术治疗高血压基底节区脑出血疗效及对血清h-FABP、8-iso-PGF2α、SF的影响[J].现代中西医结合杂志,2017,26(25):2757-2760.
[15] 赵琴. 通痹活络汤联合依达拉奉对急性脑梗死患者血清CXCL-16,MCP-1和GDF-15的影响[J].西部中医药,2022,35(1):16-20.
[16] 陈圣君,李波,陈国柱,等.血清视锥蛋白样蛋白1和CXC型趋化因子配体16及抗心磷脂抗体水平与急性脑梗死患者病情及预后的关系研究[J].中国全科医学,2021,24(27):3464-3468,3476.
[17] 田琪. 急性脑梗死病人血清Sestrin2,PTX3水平及其与病情严重程度和预后的关系[J].中西医结合心脑血管病杂志,2023,21(4):745-748.
[18] 陈志,马含晖,常明则,等.急性脑梗死患者PTX3,Cav-1,GSK-3β水平变化与神经损伤程度,预后关系[J].临床和实验医学杂志,2022,21(8):792-796.
[19] 李小琴,余广兰.急性缺血性脑卒中患者血清Cav-1和GDF-15表达水平及对预后的评估价值研究[J].现代检验医学杂志,2022,37(4):118-122.
[20] 杜超楠,杨明飞,张强,等.消瘀康胶囊对脑出血患者血肿吸收及预后的影响[J].宁夏医科大学学报,2020,42(3):275-278.
[21] 艾长思. 尤瑞克林联合静脉溶栓在急性脑梗死患者临床治疗中的应用[J].黑龙江医药科学,2023,46(1):197-198.